Comparative Pharmacology
Head-to-head clinical analysis: AUVELITY versus TRINTELLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUVELITY versus TRINTELLIX.
AUVELITY vs TRINTELLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AUVELITY (dextromethorphan HBr and bupropion HCl) is an NMDA receptor antagonist (via dextromethorphan) and a norepinephrine-dopamine reuptake inhibitor (via bupropion). Dextromethorphan also modulates sigma-1 receptor activity.
Trintellix (vortioxetine) is a serotonin modulator and reuptake inhibitor. Its exact mechanism is not fully understood, but it is thought to work by inhibiting the reuptake of serotonin (5-HT) and by modulating several serotonin receptors, including 5-HT1A agonism, 5-HT1B partial agonism, 5-HT3 and 5-HT7 antagonism.
45 mg orally once daily, given as dextromethorphan hydrobromide 45 mg and bupropion hydrochloride 105 mg combination tablet.
10 mg orally once daily initially, then increase to 20 mg orally once daily based on tolerability; maximum 20 mg/day.
None Documented
None Documented
Dextromethorphan: 13.5 hours (terminal half-life; prolonged due to CYP2D6 inhibition by bupropion, allowing sustained NMDA antagonism; bupropion: 13.7 hours)
Terminal elimination half-life is approximately 66 hours (range 58-78 hours) for vortioxetine. This supports once-daily dosing; steady-state is reached within 2-3 weeks.
Renal 81% (dextromethorphan and metabolites: 78% as unchanged drug and 3% as dextrorphan conjugates), fecal 9% (dextromethorphan and metabolites), biliary <1%
Primarily hepatic metabolism via CYP3A4 and CYP2C19, with approximately 26% of the dose recovered in urine (mostly as metabolites) and 60% in feces (mostly as metabolites). Less than 1% excreted as unchanged drug in urine.
Category C
Category C
Antidepressant
Antidepressant